MANNKIND CORP Interest Expense, Borrowings
MANNKIND CORP (MNKD) reported Interest Expense, Borrowings of $2.36 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseBorrowings · last filed 2026-08-05
- MANNKIND CORP interest expense, borrowings for the quarter ending 2026-06-30 was $2.36M, a 0.80% decline year-over-year.
- MANNKIND CORP interest expense, borrowings for the quarter ending 2026-03-31 was $2.34M, a 0.72% decline year-over-year.
- MANNKIND CORP interest expense, borrowings for the quarter ending 2025-12-31 was $2.40M, a 0.62% decline year-over-year.
- MANNKIND CORP interest expense, borrowings for the quarter ending 2025-09-30 was $2.40M, a 0.58% decline year-over-year.
- MANNKIND CORP interest expense, borrowings for fiscal 2025 was $9.54M, a 0.79% decline from fiscal 2024.
- MANNKIND CORP interest expense, borrowings for fiscal 2024 was $9.62M, a 0.02% increase from fiscal 2023.
- MANNKIND CORP interest expense, borrowings for fiscal 2023 was $9.62M, a 0.70% increase from fiscal 2022.
- MANNKIND CORP interest expense, borrowings for fiscal 2022 was $9.55M.
| Period end | Interest Expense, Borrowings 3 month | Interest Expense, Borrowings 6 month | Interest Expense, Borrowings 9 month | Interest Expense, Borrowings 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.36M 10-Q · filed 2026-08-05 | $4.71M 10-Q · filed 2026-08-05 | $7.10M derived: sum of 3 quarters · filed 2026-08-05 | $9.51M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $2.34M 10-Q · filed 2026-05-06 | $4.74M derived: sum of 2 quarters · filed 2026-05-06 | $7.14M derived: sum of 3 quarters · filed 2026-05-06 | $9.53M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $2.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $4.80M derived: sum of 2 quarters · filed 2026-02-26 | $7.18M derived: sum of 3 quarters · filed 2026-08-05 | $9.54M 10-K · filed 2026-02-26 |
| 2025-09-30 | $2.40M 10-Q · filed 2025-11-05 | $4.78M derived: sum of 2 quarters · filed 2026-08-05 | $7.14M 10-Q · filed 2025-11-05 | $9.56M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $2.38M 10-Q · filed 2026-08-05 | $4.74M 10-Q · filed 2026-08-05 | $7.15M derived: sum of 3 quarters · filed 2026-08-05 | $9.57M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $2.36M 10-Q · filed 2026-05-06 | $4.77M derived: sum of 2 quarters · filed 2026-05-06 | $7.19M derived: sum of 3 quarters · filed 2026-05-06 | $9.58M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $2.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $4.83M derived: sum of 2 quarters · filed 2026-02-26 | $7.22M derived: sum of 3 quarters · filed 2026-02-26 | $9.62M 10-K · filed 2026-02-26 |
| 2024-09-30 | $2.42M 10-Q · filed 2025-11-05 | $4.81M derived: sum of 2 quarters · filed 2025-11-05 | $7.21M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $2.39M 10-Q · filed 2025-08-06 | $4.79M 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | $2.40M 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $9.62M 10-K · filed 2026-02-26 | |||
| 2022-12-31 | $9.55M 10-K · filed 2025-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |